Recent Events & Catalysts
Relay Therapeutics, Inc. (RLAY) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
SeekingAlpha · 1d ago
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26
Benzinga · 1d ago
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30
Benzinga · 4d ago
Relay Therapeutics (NASDAQ:RLAY) Reports Q2 2026 Revenue Miss as Loss Widens Slightly
ChartMill · 4d ago
Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate
Benzinga · 5d ago
Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense
SeekingAlpha · 12d ago
SEC Filings (90 days)
Entry into a material agreement, Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-06 · 5d ago · Material
Amendments to articles or bylaws, Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-06-09 · 63d ago
Entry into a material agreement, Financial statements and exhibits
Filed 2026-05-21 · 82d ago
Regulation FD disclosure, Other events, Financial statements and exhibits
Filed 2026-05-19 · 84d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.